A Study of FB1003 in Healthy Subject - Trial NCT06343714
Access comprehensive clinical trial information for NCT06343714 through Pure Global AI's free database. This Phase 1 trial is sponsored by 4B Technologies Limited and is currently Not yet recruiting. The study focuses on Healthy Volunteers. Target enrollment is 64 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
4B Technologies Limited
Timeline & Enrollment
Phase 1
Apr 03, 2024
Jun 30, 2025
Primary Outcome
The primary endpoint in the study is the incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with FB1003 or placebo.
Summary
The purpose of this study is to evaluate safety and tolerability of FB1003 when given
 subcutaneously to healthy participants. Blood tests will be done to examine blood exposure,
 concentration and half-life of FB1003 following administrations. For each participant, the
 study will last up to about 12 weeks for single ascending dose part, and 18 weeks for
 multiple ascending dose part, including screening.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06343714
Non-Device Trial